BioCentury | Nov 13, 2019
Clinical News

Bardoxolone data set Reata up to advance second compound toward registration

Weeks after regaining rights to cardiorenal compounds from AbbVie, Reata has reported its second pivotal trial success of the quarter, paving the way for global marketing applications for its two most advanced compounds as it...
BioCentury | Sep 5, 2019
Preclinical News

2016 study on gut integrin HIV target can't be replicated

...was not wild type, but an SIVmac239 strain with a stop codon in the SIV nef...
...study in non-human primates. Fauci's group and another NIH group both used the same SIVmac239- nef...
...noted that "the use of the attenuated virus with the stop codon in the virus nef...
BioCentury | Jun 23, 2014
Emerging Company Profile

Amal: Party of two

...multi-antigenic cargo Disease focus: Cancer Clinical status: Preclinical Founded: 2012 by Madiha Derouazi and Patrick Nef...
BioCentury | Nov 14, 2013
Distillery Therapeutics

Indication: Infectious disease

...Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HIV/AIDS HIV gag polyprotein; HIV p27 (nef...
BioCentury | Feb 7, 2013
Tools & Techniques

Rejuvenating T cells

...markers CD3 and CD8. The Tokyo group, led by Hiromitsu Nakauchi, used mature HIV p27 ( nef...
...CD8 + T cells generated from the patient with HIV showed antigen-specific killing activity against nef...
BioCentury | Jan 31, 2013
Distillery Techniques

Technology: Drug platforms

...cells from an HIV-infected patient to generate T cells that showed antigen-specific activity against HIV p27 (nef...
BioCentury | Nov 1, 2012
Targets & Mechanisms

Prime and pull against HSV-2

...effect" than vaccination alone. Seek's HIV-v , a T and B cell vaccine targeting the Nef...
BioCentury | Aug 22, 2011
Company News

GenVec cancer, infectious news

...also includes an HIV vaccine that combines synthetically modified elements of HIV genes gag, pol, nef...
BioCentury | Jul 25, 2011
Clinical News

HIV-v: Phase Ib/II data

...HIV-v Business: Infectious Molecular target: HIV antigens Description: T and B cell vaccine targeting the Nef...
BioCentury | Jul 19, 2011
Clinical News

Seek reports Phase Ib/II data for HIV vaccine

...not yet required antiretroviral therapy. HIV-v is a T and B cell vaccine targeting the Nef...
Items per page:
1 - 10 of 70